Molecular Partners Management
Management criteria checks 2/4
Molecular Partners' CEO is Patrick Amstutz, appointed in Jan 2004, has a tenure of 20.33 years. total yearly compensation is CHF1.05M, comprised of 36.8% salary and 63.2% bonuses, including company stock and options. directly owns 2.24% of the company’s shares, worth CHF2.42M. The average tenure of the management team and the board of directors is 2.8 years and 4.1 years respectively.
Key information
Patrick Amstutz
Chief executive officer
CHF1.0m
Total compensation
| CEO salary percentage | 36.8% |
| CEO tenure | 20.3yrs |
| CEO ownership | 2.2% |
| Management average tenure | 2.8yrs |
| Board average tenure | 4.1yrs |
Recent management updates
Recent updates
We Think Some Shareholders May Hesitate To Increase Molecular Partners AG's (VTX:MOLN) CEO Compensation
Apr 11
Is Molecular Partners (VTX:MOLN) In A Good Position To Invest In Growth?
Jan 09Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation
Sep 08Need To Know: The Consensus Just Cut Its Molecular Partners AG (VTX:MOLN) Estimates For 2023
Jun 23What You Need To Know About The Molecular Partners AG (VTX:MOLN) Analyst Downgrade Today
Aug 31Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans
May 09Upgrade: Analysts Just Made A Substantial Increase To Their Molecular Partners AG (VTX:MOLN) Forecasts
Dec 26We're Hopeful That Molecular Partners (VTX:MOLN) Will Use Its Cash Wisely
Jun 24Molecular Partners AG (VTX:MOLN) Could Be Less Than A Year Away From Profitability
Mar 09Analysts Just Made A Major Revision To Their Molecular Partners AG (VTX:MOLN) Revenue Forecasts
Feb 10Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans
Jan 21How Much Of Molecular Partners AG (VTX:MOLN) Do Insiders Own?
Dec 17
Downgrade: Here's How Analysts See Molecular Partners AG (VTX:MOLN) Performing In The Near Term
Nov 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | CHF1m | CHF385k | -CHF62m |
| Sep 30 2023 | n/a | n/a | -CHF60m |
| Jun 30 2023 | n/a | n/a | -CHF62m |
| Mar 31 2023 | n/a | n/a | -CHF50m |
| Dec 31 2022 | CHF1m | CHF383k | CHF118m |
| Sep 30 2022 | n/a | n/a | CHF117m |
| Jun 30 2022 | n/a | n/a | CHF118m |
| Mar 31 2022 | n/a | n/a | CHF106m |
| Dec 31 2021 | CHF1m | CHF380k | -CHF64m |
| Sep 30 2021 | n/a | n/a | -CHF67m |
| Jun 30 2021 | n/a | n/a | -CHF72m |
| Mar 31 2021 | n/a | n/a | -CHF66m |
| Dec 31 2020 | CHF1m | CHF380k | -CHF63m |
| Sep 30 2020 | n/a | n/a | -CHF53m |
| Jun 30 2020 | n/a | n/a | -CHF48m |
| Mar 31 2020 | n/a | n/a | -CHF43m |
| Dec 31 2019 | CHF930k | CHF363k | -CHF36m |
| Sep 30 2019 | n/a | n/a | -CHF37m |
| Jun 30 2019 | n/a | n/a | -CHF38m |
| Mar 31 2019 | n/a | n/a | -CHF38m |
| Dec 31 2018 | CHF909k | CHF346k | -CHF37m |
| Sep 30 2018 | n/a | n/a | -CHF27m |
| Jun 30 2018 | n/a | n/a | -CHF18m |
| Mar 31 2018 | n/a | n/a | -CHF24m |
| Dec 31 2017 | CHF885k | CHF344k | -CHF25m |
Compensation vs Market: Patrick's total compensation ($USD1.14M) is above average for companies of similar size in the Swiss market ($USD607.27K).
Compensation vs Earnings: Patrick's compensation has increased whilst the company is unprofitable.
CEO
Patrick Amstutz (48 yo)
20.3yrs
Tenure
CHF1,047,000
Compensation
Dr. Patrick Amstutz, Ph.D. is a Co-Founder of Molecular Partners AG and has been its Chief Executive Officer since November 2016 and serves as its Member of Management Board since 2004. Dr. Amstutz serves...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 20.3yrs | CHF1.05m | 2.24% CHF 2.4m | |
| Co-Founder | 20.3yrs | no data | 2.34% CHF 2.5m | |
| Senior VP of Finance | 4.8yrs | no data | no data | |
| COO & Member of Management Board | 1.8yrs | no data | 0.078% CHF 84.6k | |
| Executive VP of People & Community and Member of Management Board | 2.4yrs | no data | 0.070% CHF 75.7k | |
| Senior Vice President of Research & Technology | 3.2yrs | no data | no data | |
| Senior Vice President of Investor Relations | no data | no data | no data | |
| General Counsel | 1.5yrs | no data | no data | |
| Strategic Consultant | 4.8yrs | no data | no data | |
| Senior Vice President of Research & Early Development | 2.3yrs | no data | no data | |
| Interim Chief Medical Officer | less than a year | no data | no data |
2.8yrs
Average Tenure
51yo
Average Age
Experienced Management: MOLN's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 6.6yrs | CHF1.05m | 2.24% CHF 2.4m | |
| Independent Non Executive Director | 10yrs | CHF135.00k | 0.045% CHF 48.4k | |
| Independent Chairman of the Board | 6.6yrs | CHF295.00k | 0.082% CHF 88.7k | |
| Independent Director | 4.1yrs | CHF125.00k | 0.011% CHF 11.5k | |
| Independent Director | 3.1yrs | CHF125.00k | no data | |
| Independent Director | 4.1yrs | CHF135.00k | 0.011% CHF 11.5k | |
| Independent Director | 4.1yrs | CHF130.00k | 0.011% CHF 11.5k | |
| Independent Director | 3.1yrs | CHF133.00k | no data |
4.1yrs
Average Tenure
58yo
Average Age
Experienced Board: MOLN's board of directors are considered experienced (4.1 years average tenure).